초록 ▼

The present invention relates to soluble and stable anti-VEGF immunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recom

The present invention relates to soluble and stable anti-VEGF immunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

대표청구항 ▼

1. A humanized antibody or antigen-binding fragment thereof comprising a variable heavy chain (VH), and a variable light chain (VL), wherein the VH comprises CDRH1, CDRH2 and CDRH3 sequences of SEQ ID NO: 8, SEQ ID NO: 20 and SEQ ID NO: 32, respectively, and the VL comprises CDRL1, CDRL2, and CDRL3

1. A humanized antibody or antigen-binding fragment thereof comprising a variable heavy chain (VH), and a variable light chain (VL), wherein the VH comprises CDRH1, CDRH2 and CDRH3 sequences of SEQ ID NO: 8, SEQ ID NO: 20 and SEQ ID NO: 32, respectively, and the VL comprises CDRL1, CDRL2, and CDRL3 sequences of SEQ ID NO: 43, SEQ ID NO: 55 and SEQ ID NO: 66, respectively, wherein the antibody or antigen-binding fragment thereof neutralizes human VEGF. 2. The humanized antibody or antigen-binding fragment thereof of claim 1 which specifically binds to human and rat/mouse VEGF. 3. The antigen-binding fragment of claim 1 , wherein the fragment is an scFv or Fab. 4. A composition comprising the humanized antibody or antigen-binding fragment thereof of claim 1, and a pharmaceutically acceptable carrier. 5. The composition of claim 4, formulated for topical, intraocular, oral, nasal, rectal or parental administration. 6. The humanized antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 164 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 87. 7. The antigen-binding fragment of claim 6, wherein the fragment is an scFv or a Fab. 8. The antigen-binding fragment of claim 6, wherein the fragment is a F(ab′)2 or a Fab′. 9. The antigen-binding fragment of claim 6, wherein the fragment is an scFv and wherein the heavy chain variable region and the light chain variable region are linked by the sequence of SEQ ID NO: 181. 10. A composition comprising the humanized antibody or antigen-binding fragment thereof of claim 6, and a pharmaceutically acceptable carrier.